Yevgeniy Samyshkin
6PUBLICATIONS
6CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jan 23, 2025
Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.Shinsuke Iida, Yusuke Yasutomi, Yevgeniy Samyshkin
|Mar 10, 2022
Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer.Domenica Lorusso, Holly Guy, Yevgeniy Samyshkin
|Sep 17, 2021
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.Anshul Shah, Jonathan C Tosh, Apoorva Ambavane
|Sep 01, 2021
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.Andreas Nikolaou, Apoorva Ambavane, Anshul Shah
|Dec 05, 2019
Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension.David G Kiely, Orla Doyle, Edmund Drage
|Sep 07, 2018
High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project.Rito Bergemann, James Allsopp, Harvey Jenner
Pageof 1
